Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 212Pb-VMT-alpha-NET |
Synonyms | |
Therapy Description |
212Pb-VMT-alpha-NET is a radioconjugate comprising the radionuclide 212Pb linked to a SSTR2 peptide analogue peptide, which delivers radiation to SSTR2-expressing tumor cells, potentially resulting in decreased tumor growth (J Nucl Med June 2023, 64 (supplement 1) P772, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
212Pb-VMT-alpha-NET | [212Pb] VMT-a-NET | 212Pb-VMT-alpha-NET is a radioconjugate comprising the radionuclide 212Pb linked to a SSTR2 peptide analogue peptide, which delivers radiation to SSTR2-expressing tumor cells, potentially resulting in decreased tumor growth (J Nucl Med June 2023, 64 (supplement 1) P772, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06479811 | Phase I | 212Pb-VMT-alpha-NET | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | Not yet recruiting | USA | 0 |
NCT06148636 | Phase I | 212Pb-VMT-alpha-NET | A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors | Active, not recruiting | USA | 0 |
NCT06427798 | Phase Ib/II | 212Pb-VMT-alpha-NET | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | Not yet recruiting | USA | 0 |